DE69403068D1 - Silylierte acetylcholinesterase inhibitoren - Google Patents

Silylierte acetylcholinesterase inhibitoren

Info

Publication number
DE69403068D1
DE69403068D1 DE69403068T DE69403068T DE69403068D1 DE 69403068 D1 DE69403068 D1 DE 69403068D1 DE 69403068 T DE69403068 T DE 69403068T DE 69403068 T DE69403068 T DE 69403068T DE 69403068 D1 DE69403068 D1 DE 69403068D1
Authority
DE
Germany
Prior art keywords
silylierte
inhibitoren
acetylcholinesterase
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69403068T
Other languages
German (de)
Other versions
DE69403068T2 (en
Inventor
Jean-Noel Collard
Jean-Marie Hornsperger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69403068D1 publication Critical patent/DE69403068D1/en
Publication of DE69403068T2 publication Critical patent/DE69403068T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Fluorinated silylated aromatic compounds possessing anticholinesterase activity and methods of treating Degenerative Dementias using these compounds.
DE69403068T 1993-02-16 1994-01-25 SILYLATED ACETYL CHOLINESTERASE INHIBITORS Expired - Lifetime DE69403068T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93400385A EP0611769A1 (en) 1993-02-16 1993-02-16 Silylated acetylcholinesterase inhibitors
PCT/US1994/000720 WO1994019356A1 (en) 1993-02-16 1994-01-25 Silylated acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
DE69403068D1 true DE69403068D1 (en) 1997-06-12
DE69403068T2 DE69403068T2 (en) 1997-12-11

Family

ID=8214682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69403068T Expired - Lifetime DE69403068T2 (en) 1993-02-16 1994-01-25 SILYLATED ACETYL CHOLINESTERASE INHIBITORS

Country Status (19)

Country Link
EP (2) EP0611769A1 (en)
JP (1) JP3516955B2 (en)
KR (1) KR100336547B1 (en)
CN (1) CN1043575C (en)
AT (1) ATE152725T1 (en)
AU (1) AU672885B2 (en)
CA (1) CA2154870C (en)
DE (1) DE69403068T2 (en)
DK (1) DK0684951T3 (en)
ES (1) ES2104358T3 (en)
FI (1) FI111461B (en)
GR (1) GR3024151T3 (en)
HU (1) HUT72736A (en)
IL (1) IL108623A0 (en)
MX (1) MX9401175A (en)
NO (1) NO305517B1 (en)
NZ (1) NZ262247A (en)
WO (1) WO1994019356A1 (en)
ZA (1) ZA94925B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627400A1 (en) * 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
CN100431539C (en) * 2004-01-12 2008-11-12 和泓生物技术(上海)有限公司 Use of acetylchloinesterase inhibitor for preparing medicine for treating parkinson's disease
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
MX2009009234A (en) 2007-03-01 2009-12-01 Probiodrug Ag New use of glutaminyl cyclase inhibitors.
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
ES2548913T3 (en) 2009-09-11 2015-10-21 Probiodrug Ag Heterocyclic derivatives such as glutaminyl cyclase inhibitors
CN102905532A (en) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 Methods and compositions for improving cognitive function
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EA034167B8 (en) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
CN112047973B (en) * 2019-06-06 2022-11-18 上海科技大学 Cannabinoids compound, preparation method, composition and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0403713A1 (en) * 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors

Also Published As

Publication number Publication date
MX9401175A (en) 1994-08-31
FI953851A0 (en) 1995-08-15
NO953201L (en) 1995-08-15
NO953201D0 (en) 1995-08-15
IL108623A0 (en) 1994-05-30
DE69403068T2 (en) 1997-12-11
KR960701068A (en) 1996-02-24
DK0684951T3 (en) 1997-05-26
AU6164194A (en) 1994-09-14
CN1117733A (en) 1996-02-28
FI953851A (en) 1995-08-15
JPH08507059A (en) 1996-07-30
WO1994019356A1 (en) 1994-09-01
ES2104358T3 (en) 1997-10-01
EP0684951B1 (en) 1997-05-07
GR3024151T3 (en) 1997-10-31
NO305517B1 (en) 1999-06-14
ZA94925B (en) 1994-08-25
CN1043575C (en) 1999-06-09
JP3516955B2 (en) 2004-04-05
AU672885B2 (en) 1996-10-17
EP0611769A1 (en) 1994-08-24
FI111461B (en) 2003-07-31
HUT72736A (en) 1996-05-28
KR100336547B1 (en) 2002-11-02
CA2154870A1 (en) 1994-09-01
EP0684951A1 (en) 1995-12-06
ATE152725T1 (en) 1997-05-15
NZ262247A (en) 1996-01-26
CA2154870C (en) 1998-10-27

Similar Documents

Publication Publication Date Title
DE69403068D1 (en) Silylierte acetylcholinesterase inhibitoren
ZA943787B (en) Aromatic acetylcholinesterase inhibitors
TW218869B (en)
GB2276178B (en) Treatment of textiles
GR3030269T3 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus.
EP0630383A4 (en) Methods of treating diabetes.
GR3031149T3 (en) Process for the manufacture of (s)-3-amino-1-substituted-pyrrolidines.
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
GB9217547D0 (en) Leather treatment compositions
EP0654996A4 (en) Methods of treating psoriasis employing substituted azaspiranes.
GB2269523B (en) Treating hides
EP0932406A4 (en) Methods of treating or preventing interstitial cystitis
GB9302314D0 (en) Novel compounds and treatment
GB9321592D0 (en) Novel compounds and treatment
GB9302289D0 (en) Novel compounds and treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS INC. (N.D.GES.D. STAATES PENNSYLVANIA), GR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US